Market Overview

Lannett Receives FDA Approval for Diethylpropion HCl Extended Release Tablets, 75 mg

Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Diethylpropion HCl Extended Release Tablets, 75 mg. Sales of Diethylpropion HCl Extended Release Tablets, 75 mg, at Average Wholesale Price were approximately $7.6 million on an annual basis, according to Wolters Kluwer.

Diethylpropion HCl, as with most anti-obesity drugs, primarily is sold to bariatric clinics; as a result, prescriptions do not reflect the entire market. The company expects to commence shipping immediately.

Posted-In: News FDA

 

Most Popular

Related Articles (LCI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free